Mind Medicine Inc. MNMD MMED, a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the pricing of its underwritten public offering of 7 million common shares, together with accompanying warrants to purchase 7 million common shares. The combined offering price to the public of each common share and accompanying warrant is $4.25. Each common share will be sold in combination with an accompanying warrant, and each warrant is exercisable to purchase one common share. The accompanying warrant will be immediately exercisable and has an exercise price of $4.25 per common share and expires five years from the date of issuance.
All of the securities are being sold by MindMed. The gross proceeds from the offering to MindMed are expected to be approximately $30 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about September 30, 2022, subject to customary closing conditions. No distribution under the underwritten public offering shall occur in Canada or to a person resident in Canada.
RBC Capital Markets and Cantor are acting as lead joint book-running managers for the offering. Oppenheimer & Co. is acting as a joint book-running manager for the offering.
Price Action
Photo by Giorgio Trovato on Unsplash
Related News
Why Mind Medicine (MindMed) Stock Is Diving After Hours
Clinical Research Comparing Effects Of Novel MDMA Matches In Healthy Patients Begins In Switzerland
This Psychedelics Company Is Undertaking A 1:50 Reverse Stock Split To Enter NASDAQ
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.